Mink Therapeutics Inc (INKT)

$12.42 -0.13 (-1.04%)
Market Cap 58.91M
Revenue (ttm) 0.00
Net Income (ttm) -9.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 11,300
Avg Vol 23,046
Day's Range N/A - N/A
Shares Out 4.69M
Stochastic %K 67%
Beta 0.35
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
Biotechguy21
Biotechguy21 Dec. 12 at 1:55 AM
$INKT he smart 😂😂😂
1 · Reply
Guptasulo
Guptasulo Dec. 11 at 5:10 PM
$INKT Median OS > 23 months in a "refractory setting". (refractory setting meaning those that failed chemotherapy / immunotherapy / targeted therapy). This Median covers ; "Not only gastric-only and includes testicular, pulmonary/GVHD and solid tumor oncology patients" Most of these patients in this group untreated had a median of 8-12 months only. (This is no longer about 1 patient of gastric or 1 from testicular.) This is extraordinary and unheard of. We can be expecting data drop anytime from now till Jan 2026.
0 · Reply
Biotechguy21
Biotechguy21 Dec. 10 at 1:25 PM
$AFJK $INKT = $AGEN 2.0. 🤡🤡😂😂
0 · Reply
Biotechguy21
Biotechguy21 Dec. 10 at 1:25 PM
$INKT $PTIX $AGEN These three have the Garo effect. Combined losses of 94%. What a joke. I did some research on the Clownshow yahoo mb it seems there is fraud going on and time will tell if I am right. Want to debate me? Prove me wrong? Please I want more info.
1 · Reply
Dieseld28
Dieseld28 Dec. 10 at 9:29 AM
$ENVB $ASPC $INKT
0 · Reply
Dieseld28
Dieseld28 Dec. 10 at 12:46 AM
$INKT $AFJK 2.0 💥
1 · Reply
MKush
MKush Dec. 9 at 8:58 PM
$AFJK sympathy play is $INKT
1 · Reply
trader87
trader87 Dec. 9 at 8:46 PM
$INKT the pattern is so similar to $AFJK
0 · Reply
Dancady1
Dancady1 Dec. 8 at 10:08 PM
$INKT
0 · Reply
neversurrender2024
neversurrender2024 Nov. 20 at 6:00 PM
$INKT pump it and dump it
0 · Reply
Latest News on INKT
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 20, 2025, 11:42 AM EST - 22 days ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 12:11 PM EST - 4 weeks ago

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 9:00 AM EST - 5 weeks ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 29, 2025, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 25, 2025, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Sep 18, 2025, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:15 PM EDT - 4 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Aug 14, 2025, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 31, 2025, 8:30 AM EDT - 4 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 15, 2025, 8:21 AM EDT - 5 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jul 11, 2025, 12:33 PM EDT - 5 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:33 PM EDT - 6 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

Jun 2, 2025, 9:29 AM EDT - 6 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 1:21 PM EDT - 7 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

May 15, 2025, 7:30 AM EDT - 7 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 11:28 AM EDT - 9 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 18, 2025, 7:30 AM EDT - 9 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Mar 4, 2025, 7:30 AM EST - 10 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 10 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Jan 23, 2025, 2:13 PM EST - 11 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 14, 2024, 10:47 AM EST - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

MiNK Therapeutics to Participate in September Investor Conferences

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

Biotechguy21
Biotechguy21 Dec. 12 at 1:55 AM
$INKT he smart 😂😂😂
1 · Reply
Guptasulo
Guptasulo Dec. 11 at 5:10 PM
$INKT Median OS > 23 months in a "refractory setting". (refractory setting meaning those that failed chemotherapy / immunotherapy / targeted therapy). This Median covers ; "Not only gastric-only and includes testicular, pulmonary/GVHD and solid tumor oncology patients" Most of these patients in this group untreated had a median of 8-12 months only. (This is no longer about 1 patient of gastric or 1 from testicular.) This is extraordinary and unheard of. We can be expecting data drop anytime from now till Jan 2026.
0 · Reply
Biotechguy21
Biotechguy21 Dec. 10 at 1:25 PM
$AFJK $INKT = $AGEN 2.0. 🤡🤡😂😂
0 · Reply
Biotechguy21
Biotechguy21 Dec. 10 at 1:25 PM
$INKT $PTIX $AGEN These three have the Garo effect. Combined losses of 94%. What a joke. I did some research on the Clownshow yahoo mb it seems there is fraud going on and time will tell if I am right. Want to debate me? Prove me wrong? Please I want more info.
1 · Reply
Dieseld28
Dieseld28 Dec. 10 at 9:29 AM
$ENVB $ASPC $INKT
0 · Reply
Dieseld28
Dieseld28 Dec. 10 at 12:46 AM
$INKT $AFJK 2.0 💥
1 · Reply
MKush
MKush Dec. 9 at 8:58 PM
$AFJK sympathy play is $INKT
1 · Reply
trader87
trader87 Dec. 9 at 8:46 PM
$INKT the pattern is so similar to $AFJK
0 · Reply
Dancady1
Dancady1 Dec. 8 at 10:08 PM
$INKT
0 · Reply
neversurrender2024
neversurrender2024 Nov. 20 at 6:00 PM
$INKT pump it and dump it
0 · Reply
2_logs_higher
2_logs_higher Nov. 20 at 5:50 PM
$AGEN & $INKT
0 · Reply
weichsel1
weichsel1 Nov. 20 at 5:26 PM
$INKT the company has dropped 30% in the last month for no good reason as far as I can tell is there any real news?
1 · Reply
StockNews_Live
StockNews_Live Nov. 17 at 5:11 AM
$INKT Something novel in the pipeline about hit the timeline.. Be on the watch... Will explain later.
0 · Reply
Dancady1
Dancady1 Nov. 14 at 2:42 PM
$INKT good news and good eps today and it is still down
0 · Reply
BinarFalcon
BinarFalcon Nov. 8 at 6:03 AM
$INKT reversal?
0 · Reply
DARKP00L
DARKP00L Nov. 7 at 2:23 PM
$INKT 09:07 on Nov. 07 2025 MiNK Therapeutics Presents Updated Clinical Results Evaluating Agent-797, Alone And In Combination With Anti-PD-1 Therapy, In Patients With Advanced Solid Tumors Refractory To All Approved Treatments At SITC 2025 #tradeideas
0 · Reply
Stock_Catcher
Stock_Catcher Nov. 7 at 2:01 PM
$INKT MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
0 · Reply
Rony4AM
Rony4AM Nov. 6 at 10:25 PM
0 · Reply
Dancady1
Dancady1 Nov. 4 at 5:08 PM
$INKT pos
0 · Reply
Biotechguy21
Biotechguy21 Nov. 3 at 3:20 PM
$AGEN $INKT $PTIX POS Stocls. Rotten to the core. 😂😂🤡🤡💩💩
0 · Reply
neversurrender2024
neversurrender2024 Oct. 31 at 5:18 AM
$INKT another cancer conference is just another fund raiser for garo armen....major dilution coming this way folks....
2 · Reply
Dancady1
Dancady1 Oct. 21 at 3:26 PM
$INKT
0 · Reply